1. A B C D Figure E1 MR-proANP (pmol/L) CT-proAVP (pmol/L) CRP (mg/L)
10000
1000
p<0.0002 ns ns
1000
100
MR-proANP (pmol/L)
100
CT-proAVP (pmol/L) 10 10 1 1
0.1
typ. bacterial
atypical
viral
mixed
unknown
typ. bacterial
atypical
viral
mixed
unknown C D
typ. bacterial
atypical
viral
mixed
unknown
0.1 1 10
100
1000
p=0.0002
p=0.015 ns
CRP (mg/L)
typ. bacterial
atypical
viral
mixed
unknown
0.001
0.01
0.1 1 10
100
1000
p<0.0001
p=0.025 ns
PCT (ng/mL)
Figure E1

2. A B C D Figure E2 1 2 3 4 CRB-65 score MR-proANP (pmol/L) 1 2 3 41 2 3 4 10
100
1000
10000
p<0.0001
CRB-65 score
MR-proANP (pmol/L) 1 2 3 4
0.1 10
100
1000
p<0.0001
CRB-65 score
CT-proAVP (pmol/L) C D 1 2 3 4
0.001
0.01
0.1 10
100
1000
p<0.0001
CRB-65 score
PCT (ng/mL)
Figure E2

3. A B C D Figure E3 survival death survival death CRP (mg/L) survival
10000
1000
p<0.0001
p<0.0001
1000
100
MR-proANP (pmol/L)
100
CT-proAVP (pmol/L) 10 10 1 1
0.1
survival
death
survival
death C D
1000
p=0.029
1000
p<0.0001
100
100 10
CRP (mg/L) 10
PCT (ng/mL) 1
0.1 1
0.01
0.1
0.001
survival
death
survival
death
Figure E3

4. A B C D Figure E4 ns no prior antibiotics prior antibiotics 0.1 1 10
100
1000
p<0.0001
CT-proAVP (pmol/L)
10000
p<0.0001
1000
100
MR-proANP (pmol/L) 10 1
no prior antibiotics
prior antibiotics C D
1000 ns
1000
p<0.0001
100
100 10
CRP (mg/L) 10
PCT (ng/mL) 1
0.1 1
0.01
0.1
0.001
no prior antibiotics
prior antibiotics
no prior antibiotics
prior antibiotics
Figure E4

5. A B C D Figure E5 MR-proANP (pmol/L) CT-proAVP (pmol/L)
10000
1000
p<0.0001
p<0.0001
1000
100
MR-proANP (pmol/L)
100
CT-proAVP (pmol/L) 10 10 1 1
0.1
outpatient treatment
inpatient treatment
outpatient treatment
inpatient treatment C D
1000
p<0.0001
1000
p<0.0001
100
100 10
CRP (mg/L) 10
PCT (ng/mL) 1
0.1 1
0.01
0.1
0.001
outpatient treatment
inpatient treatment
outpatient treatment
inpatient treatment
Figure E5

6. Figure E6 MR-proANP (pmol/L) CT-proAVP (pmol/L) 5000 500 500 50 50 5 5
PSI I
PSI II
PSI III
PSI IV
PSI V
PSI I
PSI II
PSI III
PSI IV
PSI V
Figure E6

7. inpatients: 28-days mortality
Figure E7

8. CRB-65 class 2-4: 28-days mortality
Figure E8